Tildrakizumab (Ilumetri, Almirall) Shows Sustained Improvements in Skin and Quality of Life in PsO Patients; Study Uses WHO 5 Well-Being Index as Primary Endpoint
Tildrakizumab (Ilumetri, Almirall) showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years, according to new long-term results from the POSITIVE study, which was presented at the European Academy of Dermatology and Venereology 2025 (EADV) in Paris, France.